Physical Disability in Patients Treated With Betaferon

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon-1beta (Betaseron, BAY86-5046)

Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY